Диссертация (1139742), страница 21
Текст из файла (страница 21)
— Vol. 43. — №7. — P. 481–487.113. Fulham M.J., Bizzi A., Dietz M.J. et al.Mapping of brain tumormetabolites with proton MR spectroscopic imaging: clinical relevance //Radiology. — 1992. — Vol. 185. — №3. — P. 675–686.114. Futterer J.J., Heijmink S.W.T.P.J. Carcinoma, Prostate / Encyclopediaof diagnostic imaging; ed. by A.L. Baert. —— Berlin, New York: Springer Verlag,2008. — Vol. 1. — P. 283–287.115.
Futterer J.J., Heijmink S.W., Spermon J.R. Imaging the malereproductive tract: current trends and future directions // Radiol. Clin. N. Am. —2008. — Vol. 46. — P. 133–147.116. Futterer, J.J., Barenstz J., Heijmijnk S.T. Imaging modalities forprostate cancer // Expert Rev. Anticancer Ther. — 2009. — Vol. 9. — №7. — P.923–937.117. . Green F.L., Page D.L., Fleming I.D. et al.
AJCC cancer stagingmanual. — 6th ed. — New York: Springer Verlag, 2002. — P. 309–316.160118. Gibbs, P., Pickles, M.D., Turnbull, L.W. Diffusion imaging oftheprostate at 3.0 Tesla // Invest. Radiol. — 2006. — Vol. 41. — №2. — P. 185–188.119. Gleason D.F. Classification of prostate carcinoma // CancerChemather Rad. — 1966. — Vol. 26. — P.
125–128.120. Issa B. In vivo measurement of the apparent diffusion coefficient innormal and malignant prostatic tissues using echo-planar imaging // J. Magn.Reson. Imaging. — 2002. — Vol. 16. — №2. — P. 196–200.121. Haaga J.R., Lanzieri C.F. Considerations: imaging of the wholebody. — 4th ed. — St. Louis, Missouri: Mosby, 2003. — Vol.
2. —P. 1715–1804.122. Hahn P., Smith I.С., Leboldus L. et al. // The classification of benignand malignant human prostate tissue by multivariate analysis of H magneticresonance spectra // Cancer Res. — 1997. — Vol. 57. — №16. — P. 3398–3401.123. Heesters M.A., Kamman R.L., Mooyaart E.L. et al. Localized protonspectroscopy of inoperable brain gliomas: response to radiation therapy // J.Nettrooncol. — 1993. — Vol.
17. — №1. — P. 27–35.124. Heidenreich A. Considerations: imaging in prostate cancer / In:Imaging in oncological urology; ed. by J.J.M.C.H. de la Rossette, M.J. Manyak,M.G. Harisinghani, H. Wijkstra. — London: Springer Verlag, 2009. —P. 269–276.125. Hricak H., Choyke P.L., Eberhardt S.C. et al. // Imaging prostatecancer: a multidisciplinary perspective // Radiology. — 2007. — Vol. 243. —№1.
— P. 28–53.126. Horn J.J., Coakley F.V., Simko F.P. et al. High-grade prostaticintraepithelial neoplasia in patients with prostate cancer: MR and MRspectroscopic imaging features-initial experience // Radiology. — 2007. — Vol.242. — №2. — P. 483–489.161127. Humphrey P.A. Prostate pathology. — Chicago: American Society forClinical Pathology, 2003 — P. 183–217.128. Jackson A., Buckley D., Parker G.J.M. Dynamic contrast-enhancedmagnetic resonance imaging in oncology. — Berlin: Springer Verlag, 2005. —P. 191–214.129.
Jung J.A., Coakley F.V., Vigneron D.B. et al. Prostate depiction atendorectal MR spectroscopic imaging: Investigation of a standardized evaluationsystem // Radiology. — 2004. — Vol. 233. — P. 701–708.130. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2009 // CACancer J. Clin. — 2009. — Vol. 59. — №4. — P. 225–249.131. Kaji Y., Kurhanewicz J., Hilricak H. et al. Localizing prostate cancerin the presence of post-biopsy changes on MR images: role of proton MRspectroscopic imaging // Radiology.
— 1998. — Vol. 206. — №3. — P. 785–790.132. Katz S., Rosen M. MR imaging and MR spectroscopy in prostatecancer management // Radiol. Clin. N. Am. — 2006. — Vol. 44. — №5 —P. 723–734.133. Kravchick S., Citron S., Peled R. et al. Using gray-scale and twodifferent techniques of color Doppler sonografy to detect prostate cancer //Urology. — 2003. — Vol. 61.
— №5. — P. — 977–981.134. Koutcher J.A., Ballon D., Graham M. et al. 31P NMR spectra ofextremity sarcoma: diversity of metabolic profiles and changes in response tochemotherapy // Magn. Reson. Med. — 1990. — Vol. 16. — №1. — P. 19–34.135. Kumar R., Nayyar R., Kumar V., Gupta N.P., Hemal A.K. et al.Potential of magnetic resonance spectroscopic imaging in predicting absence ofprostate cancer in men with serum prostate-specific antigen between 4 and 10ng/ml: a follow-up study // Urology.
— 2008. — Vol. 72. — №4. — Р. 859–863.136. Kurhanewicz J., Vigneron D.B., Nelson S.J. et al. Citrate as a in vivomarker to discriminate prostatic cancer from benign prostatic hyperplasia and162normal prostatic peripheral zone: detection via localized proton spectroscopy //Urology 1995.
— Vol. 45. — №3. — P. 459–466.137. Kurhanewicz J. et al. Prostate cancer: metabolic response tocryosurgery as detected with 3D III MR spectroscopic imaging // Radiology. —1996. — Vol. 200. — P. 489–496.138. Kurhanewicz J., Vigneron D.B., Нilricak H. et al. Three-dimensionalIII MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7cm3) spatial resolution // Radiology. —1996. —Vol. 198.
— P.795–805.139. Kurhanewicz J., Swanson M., Nelson SJ. et al. Magnetic resonancemolecular imaging of prostate cancer //J. Magn. Reson. Imaging. — 2002. —Vol. 16. — №4. — P. 451–463.140. Kutikov A., Guzzo T.J., Malkowicz S.B. Clinical approach toprostate: an update // Radiol. Clin. N. Am. — 2006. — Vol. 44. — №5. —P. 649–663.141. Lecouvet F.E., Geukens D., Stainier A.
et al. Magnetic resonanceimaging of the axial skeleton for detecting bone metastases in patients with highrisk prostate cancer: diagnostic and cost-effectiveness and comparison with currentdetection strategies // J. of Clin. Oncol. — 2007. — Vol. 25. — №22. —P. 3281–3287.142. Li S.Y., Chen M., Wang R., Zhou C. Differentiation between begingprostatic hyperplasia and prostate cancer in the transitional zone evaluated by 1Hmagnetic resonance spectroscopic imaging // Chin. Med. Sci. J. — 2007. —Vol.
22. —№4. — P. 238–242.143. Lowry M., Manton D.J., Liney G.P. et al. Citrate concentrationcorrelates with water T2 in normal prostate. — Berkeley, Calif.: Society ofmagnetic resonance, 1994. — Vol. 1. — P. 272.163144. Lynch M.J., Nicholson J.K. Proton MRS of human prostatic fluid:correlations between citrate, spermine, and myoinositol levels and changes withdisease // Prostate. — 1997. — Vol.
30. — №4. — P. 248–255.145. Maheshwari S.R. et al. The Choline/Creatine Ratio in Five BenignNeoplasms: Comparison with Squamous Cell Carcinoma by Use of in Vitro MRSpectroscopy // AJNR Am J Neuroradiol. — 1930 — 1935, November/December2000.146. Males R., Vigneron D., Nelson S. et al.
Addition of MR spectroscopicimaging to MRI significantly improves detection and localization of prostatecancer. — Berkeley, California: International society for magnetic resonance inmedicine, 1998. — P. 487.147. Males R.G., Vigneron D.B., Star-Lack J. et al. Clinical applications ofBASING and spectral/spatial water and lipid suppression pulses for prostate cancerstaging and localization by in vivo 3D 1H magnetic resonance spectroscopicimaging // Magn. Reson. Med. — 2000. — Vol. 43. — №1. — P. 17–22.148.
Manenti G., Squillaci E., Di Roma M., Carlani M., Mancino S.,Simonetti G. In vivo measurement of the diffusion coefficient in normal andmalignant prostatic tissue using thin — slice echo — planar imaging // Radiol.Med. (Torino). — 2006. — Vol. 111. — P. 1124–1133.149. McBride D.O., Miller B.L., Nikas D.L. et al. Analysis of brain tumorsusing 1H magnetic resonance spectroscopy // Surg.
Neurol. — 1995. —Vol. 44. —№2. — P. 137–144.150. Mescher M., Merkle H., Kirsch J. et al.Simultaneous in vivo spectralediting and water suppression // NMR Biomed. — 1998. — Vol. 11. — №6. —P. 266–272.151. Montironi R., Mazzucchelli R., Algaba F. et al. Morphologicalidentification of the patterns of prostatic intraepithelial neoplasia and theirimportance // J. Clin. Pathol. — 2000. — Vol. 53. — №9. — P. 655–665.164152.
Muller-Lisse U.G., Scherr M.K., Muller-Lisse U.L. Male pelvis:prostate / Magnetic resonance tomography; ed. by M.F. Reiser, W. Semmler, H.Hricak. — Berlin: Springer Verlag, 2008. — P. 1018–1039.153. Nakanishi K., Kobayashi M., Nakaguchi K. et al. Whole-body MRIfor detecting metastatic bone tumor:diagnosticvalue of diffusion-weightedimages // Magn. Reson. Med. Sci. — 2007. — Vol. 6. — №3. — P.147–155.154. NCCN—2015:HistopathologicGrade(G).—URL:https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.155. Ocak I., Bernando M., Metzger G.
et al. Dynamic contrast-enhancedMRI of prostate at 3T: a study of pharmacokinetic parameters // AKR Am. J.Roentgenol. — 2007. — Vol. 189. — №4. — P. 849.156. Otto J., Thormer G., Seiwerts M. et al. Value of endorectal magneticresonance imaging at 3T for the local staging of prostate cancer // Rofo. —2014. — Vol. 186. — №8. — P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
